Johnson & Johnson had a strong year in 2013, but what about 2014? A rival bio-similar from Hospira threatens its largest drug by sales, Remicade. In addition, a weak medical device market has already been discussed by a company like General Electric. So, where next for Johnson & Johnson? The recent earnings results from Johnson & Johnson (NYSE: JNJ) were met with a near 2% sell-off on the day.
Looking into 2014, investors should focus on three things: 1. Acceleration in the economic recovery so medical device sales can pick up inline with an increase in surgical procedures. 2. Ongoing development of pharmaceutical sales, and activity to protect future market share for Remicade in Europe. and 3. An improvement in its international consumer products sales, as they only grew 3.1% operationally in 2013. Achieving two of the three things should provide for some upside surprise, and Johnson & Johnson needs it. On current analyst estimates, it trades on a valuation of 16 times forward earnings. The company also has only 6% and 7.4% earnings-per-share growth estimated in the next two years. This makes it look like a fairly valued stock.
Source: Motley Fool
Related Articles:
- 8 Industrial Strength Stocks With Dividend Growth
- 6 Dividend Stocks To Beat The Wall Street Giants
- First Quarter 2013: Top And Bottom Performing Dividend Stocks
- A Disciplined Approach To Dividend Stocks
- 6 High-Yield REITs With Growing Dividends
Johnson & Johnson's Prospects in 2014
Posted by D4L | Monday, February 10, 2014 | ArticleLinks | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
Dividend Growth Stocks News
~
Popular Posts Last 30 Days
-
If you're worried about inflation rearing its ugly head next year, you should probably worry about more likely catastrophes, such as bei...
-
As a relatively new blogger, the one thing that has stood out in my mind is the number of Canadian bloggers in the areas that I am most inte...
-
We screened our 24/7 Wall St. dividend equity research database and found 5 stocks that combined can generate over $3,000 of annual passive ...
-
The stock market has been on an upward path of late, with some of the most prominent stocks hitting astronomical highs. The dividend yield o...
-
Dividend growth stocks can be incredibly attractive investments if you crave recurring income. As these types of stocks raise their dividend...
-
Dividends can be a tremendously powerful part of your investing strategy. Not only can they give you a continuing source of cash to reinvest...
-
The most dependable dividend stocks typically have a long track record of sustaining payouts through different market cycles. Companies with...
-
In my opinion, there are three criteria investors should consider when evaluating a particular stock for their portfolio. The first is histo...
-
In this article, we discuss 5 best March dividend stocks to buy. If you want to read our detailed analysis of dividend capture strategy and ...
-
As the broader stock rally broadens to some of the more “boring” corners of the market, it’s the higher-yielding dividend plays that could s...
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.